Compare LMFA & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LMFA | CNSP |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | 19 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 5.9M |
| IPO Year | 2015 | 2019 |
| Metric | LMFA | CNSP |
|---|---|---|
| Price | $0.22 | $5.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $5.00 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 488.0K | 65.7K |
| Earning Date | 05-15-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.66 | 8.03 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,844,733.00 | N/A |
| Revenue This Year | $4.38 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.18 | $0.73 |
| 52 Week High | $5.14 | $10.59 |
| Indicator | LMFA | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 40.27 | 51.65 |
| Support Level | $0.18 | $4.60 |
| Resistance Level | $0.27 | $5.61 |
| Average True Range (ATR) | 0.02 | 0.41 |
| MACD | -0.00 | -0.11 |
| Stochastic Oscillator | 5.36 | 39.71 |
LM Funding America Inc is a financial services company. The company provides funding to nonprofit community associations located in the state of Florida and to nonprofit community associations in the states of Washington and Colorado. Its products include Original Product and New Neighbor Guaranty. Its original product offering consists of providing funding to Associations by purchasing their rights under delinquent accounts that are selected by the Associations arising from unpaid Association assessments. It currently has two lines of business recently commenced cryptocurrency mining business and historical specialty finance business. The Company has two operating segments: Specialty Finance and Mining Operations, which generate the majority of its revenue.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.